Nanobiotix Reports Nanoprimer Breakthrough at AACR 2026

PARIS, France & CAMBRIDGE, USA, April 20, 2026

Nanobiotix has unveiled promising preclinical data demonstrating that its Nanoprimer technology significantly improves systemic bioavailability and reduces toxicity of lipid nanoparticle (LNP)-delivered DNA immunotherapy. Presented at the AACR Annual Meeting 2026, the findings highlight a critical advancement in overcoming one of the biggest limitations in modern therapeutics—rapid liver clearance and off-target toxicity. The study showed that pre-treatment with Nanoprimer enhances circulation time, reduces hepatic exposure, and mitigates inflammatory responses, positioning the platform as a potential game-changer in next-generation cancer immunotherapy delivery systems.

Nanoprimer Enhances Delivery and Reduces Toxicity

The preclinical evaluation, conducted in mouse models, assessed the impact of Nanoprimer when administered prior to LNP-delivered recombinant DNA (LNP-DNA) therapies designed for anti-tumor immunotherapy. Results demonstrated significantly improved systemic bioavailability, with higher circulating levels of therapeutic agents compared to standard administration.

Importantly, the study also showed reduced liver uptake and lower hepatic toxicity, addressing a major barrier that limits the effectiveness of advanced therapies such as gene therapies, RNA-based drugs, and biologics. Additionally, Nanoprimer pre-treatment led to attenuated activation of the cGAS-STING inflammatory pathway, reducing immune-related side effects that can compromise treatment safety. These findings underscore the platform’s ability to optimize therapeutic delivery while improving safety profiles, a key requirement for clinical success in complex biologic treatments.

Addressing a Critical Challenge in Advanced Therapeutics

A major limitation of LNP-based therapies is their rapid clearance by the liver through the mononuclear phagocyte system (MPS), which significantly reduces drug availability at target sites and increases the risk of toxicity. Nanoprimer is designed to transiently occupy these clearance pathways, allowing therapeutic agents to remain in circulation longer and reach intended tissues more effectively.

This mechanism not only enhances drug biodistribution and tumor targeting but also enables extrahepatic delivery, which is essential for expanding the therapeutic potential of emerging modalities. The data further suggest that Nanoprimer could be applied across multiple LNP designs and drug classes, making it a versatile platform technology with broad implications for oncology and beyond. By improving both efficacy and tolerability, Nanoprimer may unlock new opportunities for therapies that were previously limited by delivery challenges.

Strategic Development and Future Potential

Nanobiotix is advancing Nanoprimer through a dual development strategy, combining internal pipeline innovation with external collaborations, including partnerships with companies developing cutting-edge therapeutics.

The platform is positioned as a therapeutic companion technology, designed to enhance the performance of existing and emerging treatments. With increasing complexity in modern drug development, particularly in immunotherapy and gene-based treatments, solutions like Nanoprimer are becoming essential to address bioavailability and toxicity challenges.

The company believes that continued development of this platform could lead to improved clinical outcomes, broader therapeutic applications, and more efficient drug delivery systems.

As the healthcare industry continues to evolve toward precision medicine and advanced biologics, innovations that optimize drug delivery will play a crucial role in shaping future treatment paradigms. Nanobiotix’s latest findings position Nanoprimer as a transformational technology in the field of nanomedicine, with the potential to significantly improve the effectiveness of cancer immunotherapies and other advanced therapeutic approaches.

Source: Nanobiotix press release